Therapeutic Solutions International (OTCMKTS:TSOI) jumped 5% and up 75% in a week. The company announced that it has successfully completed various preclinical experiments as requested by the US FDA to commence phase I/II clinical studies.
Therapeutics Solutions has the only filed IND application for chronic traumatic encephalopathy treatment. The FDA requested it to conduct a series of experiments to confirm the known JadiCell stem cells properties.After completing the experiments, the company is optimistic about receiving approval to commence trials on the “first in class” CTE treatment approach.
The company has also received FDA approval to commune Phase III pivotal study to register its JadiCell stem cell for treating lung failure associated with COVID-19.Therapeutics Solutions has previously demonstrated JadiCell’s superiority relative to other stem cell types included adipose, placenta, cord blood, and bone marrow. Equally, the company has shown that JadiCell is 100% effective in saving COVID-19 patients’ lives. With positive development for JadiCell stem cells, TSOI is worth keeping an eye on.
On Thursday, TSOI stock jumped 5.33% at $0.0643 with more than 28.76 million shares, compared to its average volume of 8.41 million shares. The stock has moved within a range of $0.0610 – 0.0766 after opening the trade at $0.0670.